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Primaquine radical cure of Plasmodium vivax: a
critical review of the literature
George K John1, Nicholas M Douglas1,2, Lorenz von Seidlein2,3, Francois Nosten1,4,5, J Kevin Baird1,6,
Nicholas J White1,5 and Ric N Price1,2,7*
Abstract
Background: Primaquine has been the only widely available hypnozoitocidal anti-malarial drug for half a century.
Despite this its clinical efficacy is poorly characterized resulting in a lack of consensus over the optimal regimen for
the radical cure of Plasmodium vivax.
Methods: Published studies since 1950 of the use of primaquine regimens for preventing P. vivax relapse were
reviewed. Data were extracted systematically from available papers. Primaquine regimens were categorized
according to the total dose administered: very low (≤2.5 mg/kg), low (>2.5 mg/kg- < 5.0 mg/kg) and high
(≥ 5.0 mg/kg). The risk of recurrent infection were summarized across geographical regions and the odds ratios
between treatment regimens calculated after stratifying by total treatment dose and duration of study follow up.
Results: Data could be retrieved from 87 clinical trials presenting data in 59,735 patients enrolled into 156
treatment arms, conducted in 20 countries. There was marked heterogeneity in study design, particularly
primaquine dosing and duration of follow up. The median rate of recurrence following very low dose of
primaquine (n = 44) was 25% (range 0-90%) at 4–6 months, compared to 6.7 % (range 0-59%) following low dose
primaquine (n = 82). High dose primaquine regimens were assessed in 28 treatment arms, and were associated with
a median recurrence rate of 0% (Range: 0-15%) at one month. In 18 studies with control arms, the effectiveness of a
very low dose primaquine regimen was no different from patients who did not receive primaquine (OR = 0.60, 95%
CI 0.33-1.09, p = 0.09), whereas for the low dose regimens a significant difference was reported in 50% (6/12) of
studies (overall OR = 0.14, 95%CI: 0.06-0.35, p < 0.001). Two studies enrolling 171 patients demonstrated high
effectiveness of high dose primaquine compared to a control arm (OR = 0.03 (95%CI: 0.01-0.13); p < 0.0001).
Conclusions: Low dose regimens retain adequate efficacy in some areas, but this is not uniform. The efficacy and
safety of pragmatic high dose primaquine regimens needs to be assessed in a range of endemic and geographical
locations. Such studies will require a prolonged period of follow up and comparison with control arms to account
for confounding factors.
Background
Over 40% of the world’s population is at risk of infection
with Plasmodium vivax, with an annual global burden
estimated to be between 71 to 391 million clinical cases
[1-3]. Vivax malaria causes significant morbidity and
associated mortality, much of which is attributable to
the chronic relapsing nature of the infection. As malaria
control efforts intensify in malarious areas co-endemic
for P. vivax and Plasmodium falciparum, the relative
proportion of P. vivax tends to rise when compared to
that of P. falciparum, reflecting the greater challenge for
the control and elimination of this parasite. This can be
explained by the ability P. vivax to develop hypnozoite
stages, which can lie dormant for months or even years.
The number and frequency of P. vivax relapses vary with
a number of factors including the geographical region
where the infection is acquired, host immunity and the
sporozoite load at the time of infection. The geograph-
ical differences in relapse patterns have been attributed
to the existence of different strains of P. vivax which
* Correspondence: rprice@menzies.edu.au
1Centre for Tropical Medicine, Nuffield Department of Clinical Medicine,
University of Oxford, Oxford, UK
2Global Health Division, Menzies School of Health Research, Charles Darwin
University, PO Box 41096, Casuarina, Darwin NT 0811, Australia
Full list of author information is available at the end of the article
© 2012 John et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
John et al. Malaria Journal 2012, 11:280
http://www.malariajournal.com/content/11/1/280
vary in the proportion of sporozoites that are committed
to dormancy, the duration of dormancy and the propensity
of dormant stages to re-awaken [4]. The frequent relapse
phenotype is epitomized by the Chesson strain isolated ori-
ginally from the island of New Guinea and thought to be
prevalent in tropical regions, such as Southeast Asia,
Oceania and parts of the Indian subcontinent. These infec-
tions demonstrate the shortest relapse interval of approxi-
mately three weeks. In contrast North Indian, Madagascar
and St. Elizabeth (United States and Southern Europe)
strains follow a pattern of early relapses followed by a long
interval before subsequent relapses, whereas the first re-
lapse of the hibernans strains (Korea, Netherlands,
Scandinavia, Central Russia) is delayed by 8–12 months
[4]. Such variation in relapse patterns, the absolute risk of
recurrence and the delay in clinical manifestations repre-
sent major confounding factors undermining the inter-
pretation of primaquine efficacy.
The anti-malarial properties of primaquine, an 8-
aminoquinoline, were first documented in 1946. The drug
showed activity against both asexual and sexual blood
stages of the parasite as well against the liver stage schi-
zonts and hypnozoites [5-7]. Since the 1950s, clinicians and
policy makers have relied on primaquine as the only
licensed agent for the radical cure of P. vivax. However,
despite over 60 years of continuous use there is still neither
evidence nor consensus on the optimal dose or dosing regi-
men. Although primaquine pharmacokinetics have been
well characterized in studies of healthy subjects and adult
males with malaria, there are virtually no data available in
young children or pregnant women, the most vulnerable
populations in urgent need of an effective radical cure.
Primaquine can result in significant haemolysis par-
ticularly in those with glucose-6-phosphate dehydrogen-
ase deficiency (G6PDd) [8,9]. G6PD deficiency is the
most common heritable enzymopathy in the world, with
a prevalence ranging from 2% to 40% [10]. Generally,
the more severe the enzyme deficiency, the greater the
severity of haemolysis; individuals with less than 10% of
normal enzyme activity being at risk of life-threatening
haemolysis even after a single dose of primaquine [11].
Individuals with milder variants may have negligible
effects on exposure to primaquine [12]. In view of the
risk of adverse reactions, primaquine dosing strategies
are influenced more by concerns over toxicity than by
their absolute efficacy. These concerns are particularly
important in poorly resourced settings where routine
G6PDd testing is not available. Early clinical studies
demonstrated that the predominant determinant of
therapeutic efficacy was the total dose of primaquine
administered rather than the daily dosage or duration of
therapy [13]. Some policy makers therefore attempt to
mitigate the risk of serious harm by opting for a lower
daily dose spread over 14-days or a single weekly dose
for 8 weeks for G6PDd patients [14]. Ultimately the
effectiveness of such regimens is dependent upon adher-
ence, which is a function of a range of factors, particularly
tolerability, the duration of therapy and supervision of drug
administration.
The World Health Organization (WHO) guidelines for
the radical cure of vivax malaria currently recommends
the use of a daily dose of 0.25 mg/kg/day (3.5 mg/kg
total dose) primaquine taken with food once daily, co-
administered with chloroquine or artemisinin combin-
ation therapy (ACT) depending on chloroquine sensitivity
in the region [15,16]. In South East Asia and Oceania, the
same guidelines recommend an increase in the daily dose
to 0.5 mg/kg (7.0 mg/kg total dose) in view of the high
proportion of relapses. However there is a lack of data
regarding the benefits of the higher dose, particularly from
studies with prolonged follow up. In this paper we present
a systematic review of the literature to highlight the diver-
sity of methodologies that have been applied to anti-
relapse clinical trials and to summarize the evidence of
primaquine efficacy for different regimens across a range
of epidemiological and geographical locations.
Methods
Literature search
A MEDLINE search was conducted for all studies on
malaria using the search terms “malaria or Plasmodium”
and all possible anti-malarial drugs; Additional file 1.
This database was then filtered for clinical studies and
studies containing “vivax” and “primaquine” in the title
or abstract. In addition, the Cochrane Central Register
of Controlled Trials (CENTRAL) was searched using the
terms “(malaria or vivax) and primaquine”. Reference
lists of previously published reviews and papers on
primaquine were also screened for relevant studies in
English.
Data extraction
Data regarding study characteristics, recurrence and side
effects were systematically extracted from the articles and
entered into an EpiInfoTM 3.5.1 database and analyzed
using SPSSW Statistics vs19. Details of the study method-
ology including study site, inclusion and exclusion criteria,
identification of clinical setting, randomization and blind-
ing were extracted from all studies (Additional file 2). The
details of the dosing regimen such as co-administered
drug, primaquine dosing, frequency, duration and supervi-
sion of treatment were extracted for each arm of included
studies. The dose of primaquine was calculated according
to the total dose per kg assuming a 60 kg adult, and cate-
gorized as very low dose (≤2.5 mg/kg), low dose (>2.5 mg/
kg- < 5.0 mg/kg) and high dose (≥ 5.0 mg/kg). Study sites
were identified using Google Earth™ and GPS co-ordinates
presented using GPS online visualizer [17].
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Statistical analysis
The risk of recurrence was calculated according to a per
protocol analysis using the number of patients with re-
current P. vivax during follow up, divided by the num-
ber of patients followed until the study endpoint. The
analysis of the risk of recurrence was recorded only once
for each treatment arm, at the maximum period of fol-
low up. Recurrence rates were then presented according
to the total dose of primaquine stratified by geographical
regions. Studies carried out in the USA recruited a mix
of soldiers returning from the war in Korea, Vietnam
and Somalia as well as induced malaria using Chesson
and West Pakistan strains; for the purposes of analysis
these were categorized according to origin of the infect-
ing strain. Recurrence rates following anti-relapse treat-
ment were categorized into three groups: “Adequate
Responders” if there were less than 10% recurrence in
studies with greater than 90 days follow up and “Poor
responders” for studies with recurrence rate greater than
or equal to 10% at any time during follow up. Studies
with recurrence rates less than 10% but of short duration
(< 90 days) were categorized as indeterminate. Studies
with a control arm without primaquine were compared
by Mantel-Haenszel odds ratios (OR), calculated using
Review Manager (RevMan version 5.1. Copenhagen). Re-
currence data after primaquine regimens at 1 month, 2–
3 months, 4–6 months and 6 months were calculated
using the Mann–Whitney U test, using SPSS vs19.0 for
windows software (SPSS Inc., Chicago, Illinois).
Nomenclature
Relapse refers to the phenomenon of activation of dor-
mant P. vivax hypnozoites in the liver leading to a mal-
arial attack. Recurrence, on the other hand, is a blanket
term encompassing a repeat malarial infection which
can be caused by either recrudescence, relapse or re-
infection [18,19] There is currently no reliable way of
distinguishing between the three alternatives causes of
recurrence [20] . In this article results are reported with
regard to recurrences of P. vivax malaria.
Results
Details of included studies
A total of 120 clinical trials of primaquine were identi-
fied, of which 33 studies were excluded for the reasons
listed in Figure 1. Of the 87 clinical trials included in the
analysis, 43 (49%) were conducted on or after 2000
(Additional file 3). The greatest number of trials came
from Thailand (24 studies) followed by India (17 stud-
ies); see Figure 2. Three studies in Germany, Israel and
Taiwan enrolled travelers to endemic countries returning
with imported P. vivax malaria. Studies conducted in the
United States recruited soldiers returning from wars in
Korea (n = 3), Vietnam (n = 2) and Somalia (n = 2) or
artificial inoculation of P. vivax in inmates of state peni-
tentiaries (n = 7). None of the studies enrolled pregnant
women. Details of the studies are provided in Additional
files 4 and 5.
Design of the reviewed trials
There was marked heterogeneity in the design of the
clinical studies (Table 1) and dosing strategies of prima-
quine investigated (Additional file 4). In total 54 studies
reported comparative drug trials, of which 30 (56%) were
randomized. The median number of treatment arms in
these comparative studies was 3 (range 2–9), with 18
studies having a control arm in which patients did not
receive anti-relapse therapy. The remaining studies
were either single arm cohort studies (n=28) or retrospect-
ive (n=5).
Age-related inclusion criteria were recorded for 59
studies, of which 33 (56%) actively excluded children less
than 14 years old. Parasitaemia criteria were applied for
enrolment in 13 (15%) studies, the threshold for inclu-
sion varying from greater than 40 asexual parasites/μl to
less than 100,000 parasites/μl. Only 23 (26%) studies
reported actively testing and excluding patients with
G6PD deficiency. In 31 studies, patients with a history of
recent treatment were excluded, the interval since prior
treatment varying from 48 hours to 2 months.
The median duration of follow up was 180 days, ran-
ging from 28 to 2,555 days (Additional file 4), and dif-
fered markedly with the location of the studies. The
majority of studies conducted in Southeast Asia and
Oceania (Thailand, Indonesia, Vietnam and Papua New
Guinea) were of short duration, 70% (21/30) with no more
than a month of follow up. Conversely follow up was con-
tinued for 6 months or more in 80% (9/12) of the South
American studies and 90% (19/21) of studies on the Indian
subcontinent.
Primaquine dosing regimens
Very low total dose primaquine was used in 44 (28%) of
156 treatment regimens, low dose in 82 regimens (53%)
and high dose in 28 regimens (18%). In one study (two
treatment arms) the dose of primaquine was not stated;
see Additional file 5. Primaquine was administered
within 15 days in 140 (90%) of treatment regimens. The
remaining 16 treatment arms were administered weekly
or on alternate days over 21 to 98 days in studies con-
ducted in Indonesia (n = 4), Pakistan (n = 1), soldiers
returning from Vietnam or Somalia (n = 3) or induced
malaria with Chesson strain (n = 8). The supervision of
administration was recorded in 51% (44/87) studies, with
81% (60/74) of treatment arms fully supervised, 15%
(11/74) part supervised and 4% (3/74) unsupervised. In
114 (73%) treatment arms chloroquine was given as the ac-
companying schizontocidal therapy. Other schizontocides
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used included artesunate (n=17), artemether-lumefantrine
(n=1), amodiaquine (n=2), atovaquone/proguanil (n =2),
azithromycin (n=1), sulfadoxine-pyrimethamine (n=1),
halofantrine (n=1), mefloquine (n=1), quinine (n=4) and
rifampicin (n=1) and DB289 (n=1). In one study the schi-
zontocidal drug was not stated, and in another (with 2
treatment arms) patients received either chloroquine or
quinine regimens. Primaquine was used as monotherapy in
seven studies.
Risk of recurrence
The risk of recurrence according to geographical loca-
tion for different periods of follow up are presented in
Figures 3, 4, 5, 6, with further details in Additional file 5.
Studies using the very low dose regimen (Figure 3) were
conducted mostly in the Indian subcontinent (19/44) and
South America (16/44), with longer follow up (median
220 days; Range 28–1440). Across all regions, the median
recurrence rate following very low dose primaquine was
15% (range 0-16%) at 1 month, 11.5% (range 3-20%) at 2–
3 months, 25% (range 0–90) at 4–6 months, but fell to
9.2% (range 0-100%) at 7–12 months, reflecting almost ex-
clusive representation of studies originating on the Indian
subcontinent. In total 36% (16/44) of treatment arms were
categorized as having an adequate response and 61%
(27/44) having a poor response, with 1 study being indeter-
minate (Additional file 6).
Low dose primaquine was assessed in 82 treatment
arms with a median recurrence of 0.9% (range 0-30%) at
1 month, 6.8% (range 0-15%) at 2–3 months, 6.7%
MEDLINE search for all studies on malaria
14,334 studies
Clinical studies
1,038 studies
Studies on “vivax” and “primaquine”
Cochrane Central
Register of Controlled
Trials (CENTRAL)
Reference lists of
previous reviews and
papers on
primaquine
Review of individual studies
313 studies
120 clinical studies identified
Case report (1 study) Duplicate reports
(2 studies)
Primaquine given at the end
of study period (5 studies)
Insufficient information
on relapse and follow up
(1 study)
Full text unavailable
(6 studies)
Foreign language studies
without English translations
(9 studies)
Prophylaxis studies
(3 studies)
87 studies
157 trial arms
193 studies excluded
• Not radical cure regimens
• No clinical data presented
• Metanalyses
Terminal prophyl axis study
(1 study)
Follow up less than 21 days
(5 studies)
Figure 1 Profile of clinical studies included in the analysis.
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(range 0-59%) at 4–6 months and 17% (range 0-90%) at
7–12 months (Figure 4). In total 32% (26/82) of treat-
ment arms were categorized as having an adequate
response, 44% (36/82) having a poor response, 24%
(20/82) studies being indeterminate (Additional file 7). In
Thai studies low dose primaquine following chloroquine
was associated with a median recurrence rate of 0%
[Range: 0–1.5] at one month, significantly lower than in
Figure 2 Map of study sites of primaquine antirelapse studies. Foot Note: One study (yellow icon); Two studies (orange icon), Three or more
studies (red icon).
Table 1 Characteristics of selected studies
Year of publication No. of studies
≤1960 8
1961-70 3
1971-80 10
1981-90 4
1991-00 24
2001-10 36
2011 2
Study setting and participants No. of studies
Community setting 19
In-hospital setting 27
Out-patient setting 24
Soldiers 7
Travellers 3
Volunteers (induced) 7
Follow up period No. of studies
< 30 days 27
31-120 days 11
121-179 days 3
180 days 13
181-364 days 14
365 days 8
>365 days 11
Figure 3 Risk of recurrence at the end of the study following
very low dose primaquine.
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patients who initially received artesunate; (median= 4.8%
[Range: 4–11]; p = 0.009).
High dose primaquine was administered in 28 treatment
arms from 17 studies, and was associated with a median
risk of recurrence of 0% (Range: 0-15%) at 1 month
(Figure 5). In the 16 treatment arms in which primaquine
treatment was administered within 15 days the risk of re-
currence at 1 month was 0% (Range: 0-6%) compared to
12% (Range: 0-15%) in the 11 studies in which primaquine
was administered on alternate days or weekly. This differ-
ence was also apparent in studies with longer follow up:
0.6% (0–1.9%) at 7–12 months following short course
regimens compared to 15% (0-29%) at 4–6 months follow-
ing intermittently dosed regimens (Additional file 5). In
total 29% (8/28) of treatment arms were categorized as
having an adequate response, 25% (7/28) having a poor
response, with 46% (13/28) of studies being indeterminate
(Additional file 8). All of the seven primaquine treatments
categorized as having a poor response were administered
intermittently over a period of 27 days or more.
Odds of P. vivax recurrence after treatment
A total of 18 studies included patients recruited into
control arms in which no primaquine was given; two of
these studies had two control arms each; see Additional
file 5 and Figures 7, 8, 9. The diversity of the risk of re-
currence according to the duration of follow up and lo-
cation of the study site is apparent from review of the
control arms alone (see Figure 6). All but one of the six
comparative studies of very low dose primaquine were
conducted in the Indian subcontinent; the overall risk of
recurrence did not differ significantly from patients who
received no primaquine (OR= 0.60, [95%CI 0.33-1.09],
p = 0.09), although there was marked heterogeneity be-
tween studies (I2 = 82%). Low dose primaquine regimens
were significantly better than control regimens in 50%
(6/12) of studies assessed (OR= 0.14 [95% CI 0.06-0.35],
p < 0.001). Two studies demonstrate the high efficacy of
high dose primaquine when compared with a control
arm (OR= 0.03 [95%CI: 0.01-0.13]; p < 0.0001).
Three studies compared the risk of recurrence in
patients administered primaquine under direct supervi-
sion with those receiving unsupervised treatment. In the
two Thai studies recurrence rates of P. vivax were sig-
nificantly lower in the supervised treatment arms (com-
bined OR: 0.18 [95%CI: 0.06-0.57]) whereas in a study
Figure 4 Risk of recurrence at the end of the study following
low dose primaquine.
Figure 5 Risk of recurrence at the end of the study following
high dose primaquine.
Figure 6 Risk of recurrence at the end of the study in control
arms in which no primaquine was given. Footnotes for Figures 3,
4, 5 and 6: Indonesia and PNG [Closed Circles]; Thailand and
Vietnam (Open Circles), South and Central America (Open Squares);
Indian Subcontinent, Middle East and Horn of Africa (Open
Diamonds); Korea and China (Closed Diamonds). USA studies of
induced malaria and returning soldiers categorized according to
origin of infecting strain. Full details are given in Additional file 5.
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conducted in Pakistan there was no significant difference
between treatment arms; see Figure 10.
Safety data
Overall, 39 (48%) studies reported monitoring for ad-
verse effects of treatment recruiting a total of 11,466
patients (6,986 with very low dose, 3,322 with low dose,
961 treated with high dose and 197 with the dose not
stated). A total of 10 serious adverse events (SAE) were
reported potentially related to primaquine toxicity; these
are listed in Additional file 9. The overall rate of SAE
was therefore 8.7 (95% CI: 4.2-16) per 10,000. Assuming
denominators were all G6PD normal, the estimated rate
of SAEs in G6PD normal individuals was 3.0 (95% CI:
0.1-16.8) per 10,000 following low dose primaquine
and 10.4 (95% CI: 0.3-58) per 10,000 following high
dose primaquine. No deaths were reported in any
study.
Discussion
Despite the recognition that P. vivax constitutes a major
threat to human health and the goal of malaria elimin-
ation, knowledge of the optimal treatment strategies for
this parasite has changed little over 60 years. Newer
drugs with activity against liver stages of the parasite are
under development [21], but these are, at best, 5 to
10 years from reaching the global market. In the mean-
time better strategies need to be devised for delivering
safe and effective antirelapse therapy using primaquine.
The 2010 WHO guidelines recommend a total
primaquine dose of 3.5 mg/kg dose for the radical cure
of P. vivax, whilst acknowledging that in Southeast Asia
and Oceania a higher dose (7.0 mg/kg total dose) may
be warranted [15]. However, the evidence from which
these recommendations are derived is limited. Malaria
control programs prioritize acute anti-malarial policy
towards eliminating the initial threat to the patient
(i.e. from blood stage parasites), rather than preventing fu-
ture recurrences from hypnozoites. The most important
factor for primaquine treatment policy is safety rather than
efficacy [16]. However the benefits of radical cure may not
be appreciated. Early studies in soldiers returning from the
Korean War demonstrated that African-Americans were
particularly prone to primaquine-induced haemolysis
[22,23]. This risk could be mitigated by reducing the dose
and, in the Korean strains of P. vivax tested, this appeared
to be feasible without compromising efficacy.
The main findings of this review of the literature are
presented in Additional file 10. The plots presented in
Figures 3 and 4 highlight the wide range of primaquine
efficacy presented by published clinical trials. Both very
low dose and low dose primaquine were vulnerable to
Figure 7 Forest plot of the effectiveness of very low dose primaquine in studies with a control arm.
Figure 8 Forest plot of the effectiveness of low dose primaquine in studies with a control arm.
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high rates of recurrence of P. vivax (Figure 3 and 4),
whereas the use of high dose primaquine was associated
more often with acceptable efficacy [16]. The treatment
efficacy of high dose regimens appeared significantly
better when regimens are given over 14 days rather than
spread out over alternate days or weekly dosing. However
such comparisons need to be interpreted with caution,
since they are confounded by marked heterogeneity in
study design, dose regimens, and idiosyncrasies of the en-
demic setting. The frequency and the timing of relapses are
determined by sporozoite inoculum and parasite relapse
phenotype and this results in huge regional variation in the
absolute risk of recurrence independent of primaquine effi-
cacy [4,24]. Goller et al. applied a multivariate model to
compare relapses in studies conducted in Brazil, India and
Thailand demonstrating that after controlling for year of
study, study design and dose of primaquine, the overall risk
of relapse in Thailand was 10 times that in India and twice
that in Brazil [25]. Alternatively primaquine efficacy can be
gauged by comparison with a control arm in which patients
receive no primaquine, thus controlling for background
reinfection and relapse patterns. In their 2007 Cochrane
review, Galappaththy and colleagues used such an ap-
proach to control for differences in the background rates
of infection, concluding that the 5-day primaquine regi-
men was ineffective and that a 14-day low dose regimen
was 13-fold better compared to the five-day regimen [26].
Age is a major determinant of recurrent infection the
risk of recurrence falling significantly as age increases.
Although this may reflect exposure to new infections
age is also a surrogate marker of immunity. Young
patients are at greatest risk of symptomatic recurrent
infections and morbidity associated with repeated vivax
parasitaemia [27,28], and hence should be a priority for
optimizing therapeutic interventions; in practice how-
ever they are often excluded from clinical trials. Pharma-
cokinetics can differ markedly in children and simply
extrapolating dosing strategies from adults can result in
systematic under dosing as was shown convincingly with
the use of antifolates in P. falciparum [29]. Furthermore
studies in adult populations can overestimate true
primaquine efficacy since these patients are more likely
to control P. vivax parasitaemia, remain asymptomatic
or even clear the infection without treatment.
Based on the current analysis, the key elements
required for the design of informative clinical studies of
relapse prevention are presented in Additional file 11.
The duration of follow up is a crucial component of the
study design. In Southeast Asia and Oceania, early re-
lapse occurs in a high proportion of patients and marked
differences in antirelapse efficacy can be observed with
short duration of follow up. Only five studies from
Southeast Asia and Oceania (Thailand, Indonesia, Vietnam
and Papua New Guinea) continued follow-up beyond three
months. In areas with a more temperate climate the risk of
relapse is lower and relapse tends to occur late, often
months after the initial infection. In such circumstances,
short-term follow-up will fail to pick up treatment failures,
Figure 9 Forest plot of the effectiveness of high dose primaquine in studies with a control arm. Footnote for Figures 7, 8 and 9: * Indian
subcontinent; ^ USA (Korea), ^^ USA (Chesson), # Thailand, ## Indonesia, + Ethiopia.
Figure 10 Forest plot of the effectiveness of directly observed treatment in primaquine therapy.
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falsely elevating efficacy estimates. Such a situation oc-
curred in India, where a 5-dose primaquine regimen was
long heralded as an appropriate treatment strategy, but ac-
tually reflected an intrinsic low absolute risk of relapse; the
majority of relapses in adults being subclinical [29,30].
Early recurrence of P. vivax (within 21 to 63 days) is a
function of the efficacy of the initial schizontocidal treat-
ment in clearing the initial blood stage biomass as well
as the post treatment prophylaxis afforded by slowly
eliminated drugs [31]. This is highlighted in studies from
Thailand in which almost none of the patients receiving
chloroquine plus low dose primaquine had a recurrence
within one month, a reflection of the high efficacy
chloroquine in this location and its prolonged suppres-
sive activity on relapsing parasites [32,33]. In contrast in
the same location patients receiving primaquine com-
bined with short acting but effective artesunate regi-
mens, had a risk of recurrence of between 4 and 15%,
likely a better indication of the underlying primaquine
efficacy [34]. Short duration studies of primaquine with
slowly eliminated efficacious schizontocidial treatments
are therefore of limited benefit in defining anti-relapse
efficacy. Studies with long duration of follow up capture
a greater proportion of relapses, but are vulnerable to
confounding from heterologous new infections. The rise
of chloroquine resistance adds an additional complica-
tion of partial clearance of the initial blood stage bio-
mass, in which early recrudescence can be misclassified
as a relapsing infection. Currently, no reliable method
exists to differentiate relapses from re-infections and re-
crudescent infections.
Current guidelines recommend a 14 day course of
primaquine administered either once or twice daily to
reduce the risk of haemolysis and improve tolerability
from gastrointestinal disturbance. Advocating such pro-
longed courses of treatment can result in significant pro-
blems with adherence, as highlighted by the markedly
greater risk of recurrence in Thai patients receiving un-
supervised treatment compared to those in whom a
complete treatment course was confirmed [35,36]. Poor
adherence to a 14-day course of unsupervised prima-
quine is likely to have a major impact on its public
health benefit. Short-course, high dose regimens have
potential to increase patient adherence and thus effect-
iveness [34], but appropriately powered prospective
multi-centered randomized controlled trials are needed
to assess the efficacy and effectiveness of such alternative
radical curative regimens against current best practice.
The current methodology for primaquine treatment
trials can be improved and should be harmonized to fa-
cilitate comparison between different sites. The factors
highlighted in this review suggest that a minimum of six
months and perhaps even 12 months follow up is
required. Relapse is often a recurrent process rather than
a single event, hence the analysis of such trials should
focus on the incidence of treatment failure rather than
the cumulative risk of the first event, which is the
standard outcome measure for drug efficacy studies
in P. falciparum malaria. Such cohort studies have a
similar rationale as vaccine intervention studies in
which efficacy is interpreted against a control inter-
vention to account for new infections and variation
in relapse patterns. The use of a control arm intro-
duces a number of important ethical considerations.
At some sites schizontocidal treatment alone is
standard of care – governments fearing more harm
than benefit by giving primaquine to patients with-
out prior G6PDd. Although adverse events were not
reported consistently in the clinical studies reviewed,
what data that was available suggested the rate of
SAEs was 3 per 10,000 exposures to low dose prima-
quine and 10.4 per 10,000 exposures to high dose
primaquine. These figures are comparable to a risk
of 4.8 to 8.2 per 10,000 (1 per 2089 and 1 per 1217)
severe neuropsychiatric reactions following 15 and
25 mg/kg dose of mefloquine respectively [37].
Most endemic countries recommend, at least in
principle, use of primaquine with expressed warnings on
its potential toxicity in G6PDd patients. Several studies
highlight that even in areas where primaquine is recom-
mended, in practice it is prescribed rarely and even
when given, adherence and thus effectiveness is often
poor [38,39]. Investigation of different primaquine regi-
mens must also include appropriate measures of toler-
ability and be able to quantify the risk of severe adverse
events, especially in patients with different variants of
G6PDd. Here again a control arm is vital, since only
then can the consequences of recurrent episodes of mal-
aria on the health and well being of the patient be
assessed (Additional file 11).
Clinical research priorities for optimizing the radical cure
of P. vivax are presented in Additional file 12. In popula-
tions with high rates of G6PDd, particularly those with var-
iants at greatest risk of haemolysis, a critical hurdle for the
safe deployment of primaquine will be the development of
a rapid affordable point of care test. Cases of severe
haemolysis following a single dose of primaquine can have
a negative impact not only for the patient but also for pub-
lic confidence in public health interventions [40,41]. The
development of newer and inexpensive methods for field-
testing of G6PD deficiency should go hand in hand with
studies of primaquine effectiveness. Reliable exclusion of
patients at risk of severe harm opens the possibility for safer
and more effective deployment of high dose regimens. If
the elimination of vivax is to be achieved, a co-ordinate ef-
fort is needed to provide the evidence across the spectrum
of the vivax endemic world, from which to rationalize and
deploy antirelapse therapy in a safe and effective manner.
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